EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

L Ceriani, L Milan, L Cascione, A Di Rocco iD, I Kryachok, A J Davies, A Stathis, D Rossi, P W M Johnson, M Martelli, E Zucca iD

British Journal of Haematology · 2026-08 · 209 (2) · 514-523

DOI: 10.1111/bjh.70614 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 16.06.2026. Verfasst von L Ceriani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Institute of Southern Switzerland - EOC, Lugano, Switzerland. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, B-Cell, Mediastinal Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Swiss Cancer Research Foundation, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL. Baseline PET/computed tomography (CT) scans from 501 patients enrolled in the International Extranodal Lymphoma Study Group 37 (IELSG37) trial and treated with rituximab‐ and doxorubicin‐based immunochemotherapy were analysed. Functional PET parameters reflecting tumour burden (metabolic tumour volume, MTV), glucose consumption (total lesion glycolysis, TLG) and metabolic heterogeneity (MH) were calculated using a 25% maximum standard uptake value (SUVmax) segmentation threshold. Radiomic analysis was performed in 495 patients, extracting 107 features; 74 features uncorrelated with SUVmax and MTV were selected and analysed using a recursive‐partitioning classification tree (Ctree) approach. Ctree identified grey‐level run‐length matrix run variance (GLRLM‐RV), a marker of MH, as the most significant prognostic feature. Patients with low MH (GLRLM‐RV

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, B-CellMediastinal NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedDoxorubicinPrognosisRadiomicsRituximabTreatment Outcome

Stichwörter der Autor:innen

18FDG‐PET/CTPET metricsPMBCLprognostic modelsradiomics

Substanzen

DoxorubicinRituximab

Autor:innen und Institutionen

  • Imaging Institute of Southern Switzerland - EOC, Lugano, Switzerland.
  • Institute of Oncology Research, Bellinzona, Switzerland.
  • Università Della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland.
  • Division of Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Oncohematology Department, National Cancer Institute, Kyiv, Ukraine.
  • Cancer Research UK Centre, University of Southampton, Southampton, UK.

ORCID-Profile: A Di Rocco, E Zucca

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Swiss Cancer Research Foundation
  • National Institute for Health and Care Research
  • Rising Tide Foundation for Clinical Cancer Research
  • Cancer Research UK

Zitieren

APA

Ceriani, L., Milan, L., Cascione, L., Di Rocco, A., Kryachok, I., Davies, A. J., Stathis, A., Rossi, D., Johnson, P. W. M., Martelli, M., & Zucca, E. (2026). Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study. British Journal of Haematology, 209(2), 514-523. https://doi.org/10.1111/bjh.70614

Vancouver

Ceriani L, Milan L, Cascione L, Di Rocco A, Kryachok I, Davies AJ, et al. Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study. British Journal of Haematology. 2026;209(2):514-523. doi:10.1111/bjh.70614

BibTeX
@article{Ceriani2026,
  author = {Ceriani, L and Milan, L and Cascione, L and Di Rocco, A and Kryachok, I and Davies, A J and Stathis, A and Rossi, D and Johnson, P W M and Martelli, M and Zucca, E},
  title = {Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {2},
  pages = {514--523},
  doi = {10.1111/bjh.70614}
}
Kostenlos starten →